Clinical Trial

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Study acronym: LIBRETTO-321
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Protocol Amendment History 1 change
minor Completion pushed: 2027-11 -> 2028-11 2026-08-08
Trial Details
NCT Number NCT04280081
Lead Sponsor Eli Lilly and Company
Conditions Solid Tumor, Medullary Thyroid Cancer
Enrollment 77 participants
Start Date 2020-03-16
Primary Completion 2021-03-25 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-07